Blue Owl Capital

Eagle Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of injectable products, primarily targeting critical care, oncology, and orphan diseases. Utilizing the 505(b)(2) regulatory pathway, the company has successfully brought four products to market: Argatroban, Ryanodex, Belrapzo, and Bendeka. In addition to its approved products, Eagle Pharmaceuticals has several candidates in advanced stages of development, which are currently undergoing review by the Food and Drug Administration for potential approval.

Latigo Biotherapeutics is a clinical-stage biotechnology company that develops novel, non-opioid therapies for chronic pain. The company aims to target pain at its source to provide effective, rapid-acting pain relief without the risk of addiction. Their lead program targets Nav1.8, a validated human pain target, leveraging internal ion channel expertise.

Capital on Tap is a provider of a comprehensive small business credit card and spend management platform designed to meet the needs of small business owners. The company offers a user-friendly application process that takes just two minutes, allowing most applicants to receive instant credit decisions. Capital on Tap enables businesses to manage employee cards, access funding, and earn cashback, travel, and gift card rewards on every purchase. With over 200,000 customers and more than $5 billion spent on its business credit cards, the company has established itself as a significant player in the market. It has been recognized by notable publications as one of Europe’s fastest-growing businesses, reflecting its commitment to simplifying business funding and spending. Capital on Tap provides high credit limits and unlimited employee cards at no additional cost, helping business owners save time and money while ensuring efficient financial management.

Trillium Flow Technologies is a supplier of mission-critical valves, pumps, and aftermarket services tailored for various industries, including oil and gas, power generation, water and wastewater, and general industry. The company specializes in providing essential products such as pumps, valves, actuators, and steam turbines, serving clients across upstream, midstream, and downstream sectors of the oil and gas industry, as well as nuclear and fossil power generation. Trillium Flow Technologies emphasizes adding value throughout the entire process, from engineering and design to installation and ongoing operational support, aiming to establish itself as a trusted partner in its field.

Databricks Inc. is a technology company that provides a unified data analytics cloud platform designed to facilitate data engineering and collaborative data science. The company offers a comprehensive suite of tools, including a just-in-time data platform that simplifies data integration, real-time experimentation, and deployment of production applications for developers and data scientists. Key products include Databricks Delta, which combines the capabilities of data warehouses with low-latency streaming, MLflow for managing the machine learning lifecycle, and Delta Lake for handling batch and streaming data. Databricks serves a diverse range of industries, including advertising, healthcare, manufacturing, and telecommunications, and has established strategic partnerships with various organizations to enhance its offerings. Founded in 2013, Databricks is headquartered in San Francisco, California, with additional offices in London, Amsterdam, and Bengaluru.

Windward Bio is a clinical-stage biopharmaceutical company dedicated to enhancing outcomes for patients with advanced immunological diseases, focusing on severe respiratory conditions. The company is advancing a fully human monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 clinical trials. This antibody, administered subcutaneously, potently binds to the TSLP ligand, extending its half-life and silencing its effector functions. Windward Bio is also developing innovative bispecific programs for other immunological disorders, led by a team of experienced biopharmaceutical executives aiming to address significant unmet medical needs in this field.

Ikena Oncology, Inc. is a biotechnology company focused on discovering and developing biomarker-driven therapies for cancer treatment. It specializes in precision oncology by targeting pathways essential for cancer growth and therapeutic resistance, particularly within the Hippo and RAS signaling networks. The company's portfolio includes several preclinical and discovery-stage programs, such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-412, a kynurenine-degrading enzyme. Additionally, Ikena is developing IK-930, an oral small-molecule inhibitor of the TEAD transcription factor involved in the Hippo pathway. Ikena Oncology, originally founded as Kyn Therapeutics in 2016, rebranded in December 2019 and is headquartered in Boston, Massachusetts. The company aims to address significant medical needs in oncology through innovative drug development.

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Wayne, Pennsylvania, established in 2015. The company specializes in developing and commercializing targeted therapies for serious and rare genetic skin diseases, focusing on addressing the root causes of these conditions. Its lead product candidate, QTORIN, is an anhydrous gel formulated to ensure drug stability at room temperature while enabling effective distribution into skin layers where various dermatologic pathologies occur. Palvella Therapeutics is committed to serving patient populations that have been overlooked, with an initial emphasis on conditions such as microcystic lymphatic malformations and cutaneous venous malformations, leveraging its patented QTORIN platform to advance its therapeutic pipeline.

BITKRAFT Ventures, established in 2015, is a global venture capital firm headquartered in Berlin, with offices in major digital entertainment hubs such as Los Angeles, San Francisco, New York, London, Madrid, and Lisbon. The firm, led by German serial entrepreneur Jens Hilgers, specializes in early-stage investments in the gaming and esports industries, spanning North America, Europe, and Asia Pacific. BITKRAFT Ventures focuses on game developers, gaming platforms, gaming-related technology, and emerging sectors like web3, virtual reality, and blockchain applications.

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Irvine, California, specializing in the development of innovative treatments for patients with disorders of the ear, nose, and throat, as well as for those undergoing organ or cellular transplantation and individuals with autoimmune and neurodegenerative diseases. The company’s lead product, OP0201, is a surfactant-based nasal aerosol designed for patients at risk for or suffering from otitis media. Additionally, Eledon has developed a foam-based drug delivery technology, OP0101 and OP0102, aimed at delivering medications to the ear, nose, and sinus cavities. The company also focuses on the CD40L pathway, with its main compound in development, tegoprubart, being an IgG1 anti-CD40L antibody that shows promise for treating autoimmune diseases and supporting organ transplants. Eledon Pharmaceuticals was formerly known as Novus Therapeutics, Inc. before its rebranding in January 2021.

Interos Inc. is a company that specializes in supply chain assurance and risk management through its innovative platform. Founded in 2005 and headquartered in Arlington, Virginia, with an additional office in Menlo Park, California, Interos provides solutions to both the US Federal Government and private sector clients. The platform leverages advanced technologies, including machine learning and natural language understanding, to aggregate and analyze large sets of data, helping businesses identify relationships, patterns, and correlations that may pose risks to their supply chains. It offers features such as Eco-system Maps, Supplier Risk Assessments, Scoring, and Continuous Monitoring, designed to detect changes in financial, operational, governance, geographic, and cyber risks. By visualizing and analyzing these factors, Interos enables organizations to enhance their resilience and proactively mitigate potential disruptions in their business ecosystems. The company serves various sectors, including finance, consumer products, food, defense, intelligence, manufacturing, retail, and technology.

IPI Partners is an infrastructure investment firm based in Chicago, Illinois, founded in 2016. The company focuses on acquiring, developing, leasing, and operating data centers and technology-related real estate. With a strong emphasis on critical digital infrastructure, IPI Partners collaborates with major technology companies to enhance its offerings. It manages one of the largest private data center portfolios, specifically targeting the hyperscale and enterprise markets.

CloudPay is a provider of managed global payroll services tailored for multinational organizations, utilizing a single, unified SaaS platform. The company specializes in delivering end-to-end payroll solutions that ensure accurate and compliant payroll processing across over 130 countries and in more than twenty-five languages. By standardizing payroll functions across various geographies, CloudPay enhances operational efficiency, facilitates compliance, and offers greater visibility into payroll performance and costs. With over twenty years of industry experience and a client base of more than 2,500 multinational entities, CloudPay has earned recognition for its innovative technology and services, receiving multiple awards including accolades for Global Payroll Transformation and Payroll Software Product of the Year.

TG Therapeutics, Inc. is a biopharmaceutical company based in New York that specializes in the acquisition, development, and commercialization of innovative therapies for B-cell malignancies and autoimmune diseases. The company has developed a strong research and development platform focused on B-cell pathways and conducts rapid clinical testing. Its lead product, ublituximab, is a glycoengineered monoclonal antibody approved for treating relapsing forms of multiple sclerosis and is also under evaluation for non-Hodgkin lymphoma and chronic lymphocytic leukemia. Additionally, TG Therapeutics is advancing therapies such as TG-1701, a selective Bruton’s tyrosine kinase inhibitor, and TG-1801, a bispecific antibody targeting CD47 and CD19. The company maintains various strategic alliances to support its research initiatives and has several preclinical programs in development targeting additional therapeutic areas.

Cardurion Pharmaceuticals, LLC, established in 2017 and headquartered in Boston, Massachusetts, is a biotechnology company dedicated to developing innovative therapies for heart failure and other cardiovascular diseases. The company is advancing clinical programs that target PDE9 and CaMKII inhibition, utilizing its expertise in cardiovascular signaling pathways to address significant unmet patient needs.

TravelPerk is a comprehensive platform designed to streamline business travel management by consolidating booking, reporting, and support into a single solution. The platform offers a diverse selection of travel options, including flights, hotels, and car rentals, which allows users to book their travel easily while adhering to company policies. It features an automated system that integrates customer service, reporting tools, and expense management capabilities, enabling organizations to oversee their travel arrangements effectively. Additionally, TravelPerk's technology facilitates the enforcement of travel policies, cost control, and data analysis, ultimately simplifying the travel planning process for businesses and their employees.

AlphaSense, Inc. is a market intelligence platform that specializes in information discovery for research professionals. Founded in 2007 and headquartered in New York, the company has additional offices in London, Helsinki, Pune, and other locations. Its web-based platform aggregates and indexes financially relevant data from various sources, enabling users to conduct natural language searches for critical insights across filings, research, news, and other disclosures. The platform is designed to facilitate informed decision-making by providing users with the ability to set alerts, analyze data, and navigate complex information efficiently. AlphaSense serves nearly 2,000 enterprise clients, including a significant number of financial institutions and a majority of the S&P 500, who rely on its tools to drive their business decisions.

Dresser Utility Solutions specializes in engineered products for critical infrastructure within the global utility and industrial sectors. The company primarily serves the utility sector, focusing on the water and wastewater treatment segments. It manufactures a range of products including commercial and industrial natural gas meters, metering equipment, electronics, instrumentation, flow control devices, and overpressure protection solutions. Additionally, Dresser Utility Solutions addresses the needs of an ageing gas and water utility asset base, while responding to the increasing emphasis on environmental, social, and governance (ESG) considerations by providing innovative solutions for the water, gas, and electric markets worldwide.

Celcuity Inc. is a clinical-stage biotechnology company based in Minneapolis, Minnesota, focusing on cancer diagnosis and treatment. The company utilizes its CELsignia diagnostic platform, which analyzes living tumor cells to identify specific cellular processes that drive individual cancers. This innovative approach enables the discovery of new cancer sub-types that traditional molecular diagnostics may miss. Celcuity is developing diagnostic tests, including the CELsignia HSF test for HER2-negative breast cancer and the CELsignia MP test for various cancers, such as breast, lung, colon, ovarian, kidney, and bladder. By translating these discoveries into companion diagnostics, Celcuity aims to enhance therapeutic options for cancer patients and improve treatment outcomes, while also aiding pharmaceutical companies in defining targeted therapy patient populations more accurately. Founded in 2011, Celcuity is committed to advancing oncology through precise diagnostic and therapeutic innovations.

Linden Capital Partners, established in 2004, is a Chicago-based private equity firm specializing in leveraged buyouts of middle-market healthcare and life science companies across the United States. The firm focuses on investments in various healthcare sectors, including services, devices, supplies, and manufacturing, with a track record spanning over a decade and a half.

Lycia Therapeutics operates as a biotechnology company focused on discovering and developing first-in-class therapeutics using its proprietary Lysosomal Targeting Chimeras (LYTACs) platform. This platform enables the degradation of extracellular and membrane-bound proteins associated with challenging-to-treat diseases like cancer and autoimmune disorders, aiming to provide effective treatments for patients.

Context Therapeutics LLC is a clinical-stage biopharmaceutical company based in Philadelphia, Pennsylvania, focused on developing innovative therapies for hormone-responsive cancers. Founded in 2015, the company is dedicated to creating new medicines primarily for female cancers, including breast, ovarian, and endometrial cancer. Its lead program, Apristor (Onapristone XR), is an investigational Phase 2 drug targeting progesterone receptor positive metastatic breast and ovarian cancers. In addition to Apristor, Context is advancing CTX-030916, a potential oral antiprogestin for treating uterine fibroids and endometriosis. The company is also developing a preclinical program, CTIM-76, which is a bispecific antibody designed to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. Through its innovative pipeline, Context Therapeutics aims to address unmet medical needs in the treatment of solid tumors.

Korro Bio Inc., established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing nucleic acid-based therapeutics targeting specific sequences in genetic code to treat rare diseases. The company's proprietary platform enables efficient and selective RNA editing, leveraging natural processes common to all multicellular organisms. Korro Bio aims to advance this technology to effect changes in protein structure and function across multiple tissues, expanding the reach of genetic medicines with additional precision and tunability by editing RNA instead of DNA.

Park Place Technologies, LLC is a provider of third-party hardware maintenance and support services for information technology (IT) data centers. Founded in 1991 and based in Cleveland, Ohio, the company specializes in maintenance for storage, servers, and networking equipment, offering a range of services including hardware monitoring, data center relocation, hardware disposal, and upgrades. Its automated monitoring platform, ParkView, enhances service delivery by integrating 24/7 global customer support and advanced engineering, enabling immediate responses to maintenance needs. Park Place Technologies serves a diverse clientele, including government, education, healthcare institutions, cloud service providers, and IT companies. The company has established a global presence with offices in multiple countries, including the United Kingdom, Uruguay, Singapore, Canada, and various locations throughout Europe, Asia, and the Americas.

Prima Capital Advisors LLC, located in Scarsdale, New York, is an investment advisory and asset management firm that specializes in commercial real estate debt investments. The company offers a range of services aimed at insurance companies, endowments, corporate and public pension plans, and sovereign wealth funds. Prima Capital focuses on generating income for its clients through investments in commercial mortgage whole loans, commercial mortgage-backed securities, and REIT bonds. By utilizing open-ended funds and separate accounts, the firm provides tailored investment strategies designed to meet the needs of its diverse clientele, ensuring a steady income stream while navigating the complexities of the real estate market.

Kuvare Asset Management (“KAM”) is Kuvare’s institutional investment management business.

Monotype is a global provider of type intellectual property and font technologies, offering a range of solutions that include custom type design services and enterprise software for visual content marketing. The company is dedicated to enhancing digital engagement and visual expression across various platforms, catering to designers, marketers, and engineers. Its products ensure a consistent user experience across digital devices, such as printers, copiers, and mobile devices, while also providing essential text experiences in numerous software applications and operating systems. Monotype licenses its design assets and technologies to creative professionals, consumer device manufacturers, and developers, enabling them to focus on creating impactful brand experiences. Headquartered in Woburn, Massachusetts, Monotype operates internationally in markets across the United States, Europe, the Middle East, Africa, and Japan.

Pyxis Oncology, established in 2019 in Boston, Massachusetts, is a biotechnology company specializing in the development of antibody therapeutics for cancer treatment. The company focuses on promoting the body's immune response to cancer by analyzing tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and tumor cell signaling pathways within cold tumors. Pyxis aims to create novel antibody-based immunotherapies to directly kill tumor cells and address underlying pathologies that enable cancer proliferation and immune evasion, with the goal of improving patient outcomes for difficult-to-treat cancers.

RLDatix is a software company focused exclusively on patient safety and quality improvement.

BridgeBio is a biotechnology company that focuses on genetic disease therapies and develops those assets with the right approach in supporting R&D. BridgeBio creates a bridge from advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible. BridgeBio's mission is to discover, create, test, and deliver transformative medicines to treat patients with genetic diseases.

Vestwell is a developer of a digital savings platform focused on creating retirement plans for employees. The company provides automated retirement investing options tailored for registered investment advisers (RIAs), ensuring compliance with relevant rules and regulations. By streamlining the process of defined contributions for companies and their employees, Vestwell enables advisers to effectively engage with their clients while facilitating automation in retirement planning.

XOMA Corporation is a biotechnology company focused on the discovery and development of therapeutic candidates, primarily in the fields of monoclonal antibodies and innovative drug technologies. With a robust pipeline, the company is developing proprietary product candidates such as X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody for Type 2 diabetes; and therapies targeting metastatic melanoma and renal cell carcinoma. XOMA also has initiatives aimed at addressing unmet medical needs related to hyperparathyroidism. In addition to its own product development, the company licenses antibody discovery and optimization technologies and collaborates with major pharmaceutical firms, including Novartis and Takeda, to enhance clinical development efforts. Founded in 1981 and headquartered in Emeryville, California, XOMA is positioned at the forefront of biopharmaceutical innovation, contributing to advancements in healthcare.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

Hayfin Capital Management, established in 2009, is a London-based independent investment firm specializing in private credit and alternative asset management. The company offers tailored lending solutions to middle-market European companies and provides asset management services to institutional clients. Hayfin operates across Europe and the United States, with offices in London, Paris, Madrid, Frankfurt, Luxembourg, Tel Aviv, and New York. The firm employs a value-investing approach, focusing on four strategies: Direct Lending, Special Opportunities, High-Yield Credit, and Securitized Credit. Hayfin's team comprises industry generalists with expertise in managing complex restructurings, along with dedicated specialists in healthcare, shipping, and real estate.

Finastra is a global leader in financial services software, formed in 2017 through the merger of Misys and D+H. The company offers a comprehensive portfolio of solutions that encompass retail banking, transaction banking, lending, and treasury and capital markets. With a focus on open innovation, Finastra enables financial institutions of all sizes to deploy critical technology either on-premises or in the cloud. Its extensive range of offerings includes mortgage technology, payment management, and student lending solutions. Serving 48 of the world's top 50 banks, Finastra's secure and reliable platforms empower clients to enhance operations, mitigate risks, and adapt to the evolving demands of their customers. The company's broad geographical reach and scale ensure effective support for a diverse clientele, ranging from global financial institutions to community banks and credit unions.

Wellfleet Credit Partners credit business Invetsment Firm .

6sense is a developer of a predictive intelligence platform that enhances revenue growth for organizations. The company utilizes artificial intelligence, big data, and machine learning to provide comprehensive visibility across the customer journey, from brand awareness to revenue generation. Its platform captures anonymous buying signals and buyer intent data, allowing sales, marketing, and customer success teams to target the right accounts effectively. By recommending optimal channels and messages, 6sense removes guesswork and inefficiencies from the sales process, leading to improved pipeline quality, accelerated sales velocity, and higher conversion rates. Through its innovative approach, 6sense aims to empower revenue teams to grow revenue predictably and efficiently.

Ascentium Group provides financial services.

Oak Street Real Estate Capital, LLC is a real estate investment firm based in Chicago, Illinois, that focuses on private equity investments in the office, industrial, and multifamily sectors. Established in 2011, the firm manages commingled funds and separate accounts for a diverse range of clients, including family offices, institutional investors, insurance companies, and trusts. Oak Street Real Estate Capital is recognized as a minority and women-owned business enterprise, emphasizing its commitment to diversity in the investment landscape. The firm typically seeks to make investments ranging from $10 million to $50 million, catering to the needs of its high net worth and institutional clientele.

ITM Isotopen Technologien München AG is a biotechnology and radiopharmaceutical company based in Garching, Germany, focusing on the development, manufacturing, and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radionuclides for cancer treatment. Established in 2004, ITM has built a robust global supply network and accomplished GMP manufacturing capabilities. The company offers a range of products, including EndolucinBeta, a radiopharmaceutical precursor for targeted radionuclide therapy, as well as radionuclides like 225Ac and 213Bi. Additionally, ITM develops automated systems for synthesizing radiolabeled biomolecules and provides GMP radiolabeling services. With a growing portfolio of innovative treatments and partnerships, ITM aims to enhance patient outcomes and quality of life in oncology, specifically addressing conditions such as neuroendocrine cancers and bone metastases while minimizing side effects.

Crusoe AI Data Center is a joint venture of Crusoe, Blue Owl Capital and Primary Digital Infrastructure. The eight buildings are engineered for unparalleled scale, each capable of running up to 50,000 NVIDIA GB200 NVL72 units on a unified, integrated network fabric. This cutting-edge design pushes the boundaries of data center architecture, specifically for AI training and inference tasks. Additionally, the facilities will utilize advanced direct-to-chip liquid cooling systems that employ zero-water evaporation technology, continuously recirculating water in a closed loop to maximize efficiency and sustainability.

Crusoe AI Data Center is a joint venture of Crusoe, Blue Owl Capital and Primary Digital Infrastructure. The eight buildings are engineered for unparalleled scale, each capable of running up to 50,000 NVIDIA GB200 NVL72 units on a unified, integrated network fabric. This cutting-edge design pushes the boundaries of data center architecture, specifically for AI training and inference tasks. Additionally, the facilities will utilize advanced direct-to-chip liquid cooling systems that employ zero-water evaporation technology, continuously recirculating water in a closed loop to maximize efficiency and sustainability.

Consumer Cellular is a postpaid mobile virtual network operator based in Portland, Oregon, founded by John Marick and Greg Pryor in 1995. The company specializes in providing cellular services and devices tailored to users aged 50 and above, with a focus on no-contract cellphone plans. Consumer Cellular offers a range of products including mobile phones, smart phones, SIM cards, wireless home phone bases, and mobile hotspots. These are sold through retailers such as Target, the American Association of Retired Persons (AARP), and directly online. The company leases network capacity from AT&T and T-Mobile to provide its services.